Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:CORT NASDAQ:JAZZ NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.25+0.7%$2.14$1.54▼$5.50$77.79M1.261.14 million shs2.61 million shsCORTCorcept Therapeutics$60.22$44.79$28.66▼$91.00$6.46B0.361.27 million shs536,007 shsJAZZJazz Pharmaceuticals$239.83$202.44$105.00▼$243.32$15.05B0.27934,076 shs549,784 shsSUPNSupernus Pharmaceuticals$48.21$49.99$30.83▼$59.68$2.80B0.57778,535 shs526,839 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%+8.24%+28.07%-6.07%+12.81%CORTCorcept Therapeutics0.00%+6.83%+30.74%+70.40%-23.47%JAZZJazz Pharmaceuticals0.00%+4.83%+22.04%+38.43%+121.92%SUPNSupernus Pharmaceuticals0.00%-2.47%-3.11%-4.89%+50.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.25+0.7%$2.14$1.54▼$5.50$77.79M1.261.14 million shs2.61 million shsCORTCorcept Therapeutics$60.22$44.79$28.66▼$91.00$6.46B0.361.27 million shs536,007 shsJAZZJazz Pharmaceuticals$239.83$202.44$105.00▼$243.32$15.05B0.27934,076 shs549,784 shsSUPNSupernus Pharmaceuticals$48.21$49.99$30.83▼$59.68$2.80B0.57778,535 shs526,839 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%+8.24%+28.07%-6.07%+12.81%CORTCorcept Therapeutics0.00%+6.83%+30.74%+70.40%-23.47%JAZZJazz Pharmaceuticals0.00%+4.83%+22.04%+38.43%+121.92%SUPNSupernus Pharmaceuticals0.00%-2.47%-3.11%-4.89%+50.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.25Hold$13.50501.34% UpsideCORTCorcept Therapeutics 2.75Moderate Buy$70.8317.62% UpsideJAZZJazz Pharmaceuticals 2.84Moderate Buy$241.530.71% UpsideSUPNSupernus Pharmaceuticals 2.43Hold$62.1728.95% UpsideCurrent Analyst Ratings BreakdownLatest CORT, ANVS, JAZZ, and SUPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026JAZZJazz Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$232.00 ➝ $301.005/21/2026JAZZJazz Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$229.005/21/2026JAZZJazz Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/19/2026JAZZJazz Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $307.005/13/2026CORTCorcept Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$44.00 ➝ $72.005/7/2026JAZZJazz Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$245.005/6/2026JAZZJazz Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$239.005/6/2026JAZZJazz Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$220.00 ➝ $275.005/6/2026JAZZJazz Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$252.005/6/2026JAZZJazz Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $234.005/6/2026JAZZJazz Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$195.00 ➝ $258.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.09 per shareN/ACORTCorcept Therapeutics$761.41M8.49$0.90 per share66.71$5.94 per share10.14JAZZJazz Pharmaceuticals$4.44B3.39$16.26 per share14.75$72.24 per share3.32SUPNSupernus Pharmaceuticals$718.95M3.89$3.78 per share12.77$18.55 per share2.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%N/ACORTCorcept Therapeutics$99.65M$0.35172.0636.94N/A6.14%7.40%5.76%7/30/2026 (Estimated)JAZZJazz Pharmaceuticals-$356.15M-$0.02N/A10.800.430.66%14.56%5.25%8/4/2026 (Estimated)SUPNSupernus Pharmaceuticals-$38.55M-$0.51N/A13.351.04-3.74%13.07%9.66%8/4/2026 (Estimated)Latest CORT, ANVS, JAZZ, and SUPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/5/2026Q1 2026JAZZJazz Pharmaceuticals$4.67$6.34+$1.67$4.43$978.66 million$974.98 million4/30/2026Q1 2026CORTCorcept Therapeutics-$0.1085-$0.30-$0.1915-$0.30$185.83 million$164.90 million3/31/2026Q1 2026JAZZJazz PharmaceuticalsN/A$6.34N/A$4.43N/A$1.07 billion3/13/2026Q4 2025ANVSAnnovis Bio-$0.3084-$0.39-$0.0816-$0.39N/AN/A2/25/2026Q4 2025JAZZJazz Pharmaceuticals$6.49$6.64+$0.15$3.21$1.17 billion$1.20 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A1.275.80CORTCorcept TherapeuticsN/A2.862.77JAZZJazz Pharmaceuticals0.952.041.85SUPNSupernus PharmaceuticalsN/A1.961.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%CORTCorcept Therapeutics93.61%JAZZJazz Pharmaceuticals89.14%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%CORTCorcept Therapeutics20.70%JAZZJazz Pharmaceuticals4.30%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableCORTCorcept Therapeutics300107.35 million85.13 millionOptionableJAZZJazz Pharmaceuticals2,89062.74 million60.05 millionOptionableSUPNSupernus Pharmaceuticals58058.04 million52.93 millionOptionableCORT, ANVS, JAZZ, and SUPN HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to BuyMay 23 at 1:40 AM | americanbankingnews.comSupernus Reaches Milestone, Triggers Contingent Value Rights PaymentMay 20, 2026 | tipranks.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.com3 growth stocks we approach with cautionMay 15, 2026 | msn.com5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings CallMay 15, 2026 | finance.yahoo.comSupernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSupernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at Wall Street ZenMay 9, 2026 | marketbeat.comSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care ConferenceMay 6, 2026 | globenewswire.comDoes Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)?May 6, 2026 | finance.yahoo.comSUPN Q1 deep dive: Growth products drive revenue upside, guidance highlights execution challengesMay 6, 2026 | msn.comSupernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat EstimatesMay 6, 2026 | finance.yahoo.comSupernus Pharmaceuticals Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comSupernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSupernus Pharmaceuticals Earnings Call Signals Growth MomentumMay 5, 2026 | tipranks.comSupernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 5, 2026 | zacks.comSupernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue EstimatesMay 5, 2026 | zacks.comSupernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 EarningsMay 5, 2026 | quiverquant.comQSupernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings ResultsMay 5, 2026 | marketbeat.comSupernus Announces First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comSupernus Pharmaceuticals Q1 2026 earnings previewMay 5, 2026 | msn.comSupernus Pharmaceuticals, Inc. $SUPN Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCORT, ANVS, JAZZ, and SUPN Company DescriptionsAnnovis Bio NYSE:ANVS$2.24 +0.02 (+0.67%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$2.28 +0.03 (+1.34%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Corcept Therapeutics NASDAQ:CORT$60.22 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$60.25 +0.03 (+0.05%) As of 05/22/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Jazz Pharmaceuticals NASDAQ:JAZZ$239.83 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$238.47 -1.36 (-0.57%) As of 05/22/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Supernus Pharmaceuticals NASDAQ:SUPN$48.21 0.00 (0.00%) As of 05/22/2026 04:00 PM EasternSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
